1. Fiocchi C. Closing fistulas in Crohn’s disease: should the accent be on maintenance or safety? N Engl J Med. 2004; 350:934–936.
Article
2. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008; 6:644–653.
Article
3. Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014; 39:447–458.
Article
4. Osterman MT, Sandborn WJ, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology. 2014; 146:941–949.
Article
5. Poullenot F, Seksik P, Beaugerie L, et al. Risk of incident cancer in inflammatory bowel disease patients starting anti-TNF therapy while having recent malignancy. Inflamm Bowel Dis. 2016; 22:1362–1369.
Article
6. Axelrad JE, Fowler SA, Friedman S, Ananthakrishnan AN, Yajnik V. Effects of cancer treatment on inflammatory bowel disease remission and reactivation. Clin Gastroenterol Hepatol. 2012; 10:1021–1027.
Article
7. Stobaugh DJ, Deepak P, Ehrenpreis ED. Su1144 A predictive model of the risk of developing multiple cancers with tumor necrosis factor alpha inhibitor therapy among patients with inflammatory bowel disease. Gastroenterology. 2013; 144(5 Suppl 1):S410.
Article
8. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006; 24:2283–2289.
Article
9. Lees CW, Ironside J, Wallace WA, Satsangi J. Resolution of non-small-cell lung cancer after withdrawal of anti-TNF therapy. N Engl J Med. 2008; 359:320–321.
Article
10. Phan H, Weideman RA, Cipher DJ, Feagins LA. Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy. Intest Res. 2020; 18:282–288.
Article